Heal-Or Announces Auspicious Results of Clinical Trials with HO-03-03 for Curing Chronic Wounds
Heal-Or, a biopharmaceutical company focused on the development of therapeutics for wound healing and various skin disorders announced auspicious results of phase I clinical trials with its leading product "HO-03-03" for curing chronic wounds, that are currently conducted in 3 medical centers in Israel. The company has recently begun the regulatory practice necessary for receiving FDA approval to conduct clinical trials in the US.
According to Heal-Or founder Dr. Tamar Tennenbaum: "In all of our preclinical studies, veterinary field trials as well as in our current phase I clinical trials, the 'HO/03/03' has shown to induce healing of non-healing diabetic ulcers and other types on chronic animal wounds as well as to significantly shorten time to heal and improve esthetics of chronic wounds". Dr. Tennenbaum says the encouraging results achieved in the pre-clinical stage enabled the company to pursue clinical trials in 3 Israeli medical centers, with substantially auspicious results already. The company is expected to receive an FDA approval to conduct clinical trials in the US at the beginning of 2007.
Heal-Or`s solution is based on a family of enzymes called Protein Kinase C (PKC), that instruct the skin to complete certain tasks at certain times during the wound healing process. Where one isoform of PKC may be involved in wound closure, another one may be responsible for keeping the wound uninfected or ensuring that the epidermal cells remain unscarred. By isolating particular isoforms and their respective inhibitors and activators, Heal-Or can moderate and stimulate certain steps of the wound healing process that are not working properly.
Other news from the department research and development
